Loading...
•
Sep 30, 2023
Pacira Q3 2023 Earnings Report
Pacira BioSciences reported financial results for the third quarter of 2023.
Key Takeaways
Pacira BioSciences reported third-quarter revenue of $163.9 million and net income of $10.9 million, or $0.23 per share. Adjusted EBITDA was $52.9 million. The company revised its full-year EXPAREL guidance to $535 million to $540 million.
Total revenues of $163.9 million.
Net product sales of $128.7 million for EXPAREL.
Net product sales of $28.8 million for ZILRETTA.
Net product sales of $5.3 million for iovera°.
Revenue by Segment
Forward Guidance
Pacira revised its full-year EXPAREL guidance and reiterated its full-year financial guidance for ZILRETTA, iovera, Non-GAAP gross margin, Non-GAAP R&D expense, Non-GAAP SG&A expense, and Stock-based compensation.
Positive Outlook
- ZILRETTA net product sales of $110 million to $115 million.
- iovera° net product sales of $17 million to $20 million.
- Non-GAAP gross margin of 73% to 74%.
- Non-GAAP R&D expense of $70 million to $80 million.
- Non-GAAP SG&A expense of $220 million to $230 million.
Challenges Ahead
- Full-year EXPAREL net product sales of $535 million to $540 million versus the company’s previously guided range of $550 million to $560 million.
- Stock-based compensation of $46 million to $49 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...